Zevra Therapeutics misses Q3 revenue estimates

Zevra Therapeutics

05/11/2025 22:24

Overview

Zevra Q3 2025 revenue of $26.1 mln missed analyst expectations

Net loss for Q3 2025 reduced significantly compared to Q3 2024

Revenue growth driven by MIPLYFFA performance in Niemann-Pick disease type C

Outlook

Company did not provide specific guidance for future quarters or years in press release

Result Drivers

MIPLYFFA PERFORMANCE - MIPLYFFA contributed $22.4 mln to Q3 revenue, driving overall revenue growth

OLPRUVA STRATEGY - Co scaling back OLPRUVA sales efforts due to limited market access, maintaining availability

PIPELINE PROGRESS - EMA reviewing arimoclomol for NPC; Celiprolol Phase 3 trial enrollment ongoing

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$26.06 mln
$26.63 mln (8 Analysts)
Q3 Net Income
-$544,000
Q3 Income from Operations
$4.14 mln
Q3 Operating Expenses
$20.37 mln
Q3 Pretax Profit
-$977,000


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Zevra Therapeutics Inc is $25.00, about 60.8% above its November 4 closing price of $9.79

The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 13 three months ago

Press Release: ID:nGNX7RNSm

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)